RESUMO
Abstract Objective: To determine the prevalence of depressive disorder in patients with HIV/AIDS receiving HAART; to determine the effect of depressive disorder on adherence to antiretroviral therapy; and to determine the significance of the association. Method: The study was conducted amongst outpatients of Ahmadu Bello University Teaching Hospital, Zaria. A sociodemographic and drug adherence questionnaire was administered. The Centre for Epidemiological Studies Depression Scale(CES-D) was used to screen for depressive symptoms while the Schedule for Clinical Assessment in Neuropsychiatry (SCAN) was used to confirm the diagnosis of depressive disorder. Results: A total of 310 patients with HIV/AIDS receiving HAART participated in the study. 68.4% were female and the mean age was 35.5 (± 8.97 years). 37.4% had secondary education, while 27.1% had tertiary education. Sixty-six participants (21.3%) had significant depressive symptoms while 14.2% met ICD-10 diagnostic criteria for depressive disorder. Overall, 73% of participants had good adherence to HAART. 63.6% of participants with depressive disorder had poor adherence to HAART compared to 21.1% of participants without depressive disorder (p<0.05). Conclusion: Depressive disorder in patients with HIV/AIDS is associated with poor adherence to antiretroviral medication. Early identification and treatment of depression in such patients may improve antiretroviral medication adherence and treatment outcomes
Assuntos
Síndrome da Imunodeficiência Adquirida , Infecções por HIV , Adesão à Medicação , EnsinoRESUMO
Background: Chronic myeloid leukaemia (CML); with a median age of 40 years; is one of the commonest haematological malignancies in Nigeria. Cytoreductive agents; which were hitherto the mainstay of treatment; neither induce cytogenetic nor haematologic remission. Alpha-interferon (a-IFN); an endogenous glycoprotein with cytotoxic and natural killer cell enhancer effects has been found to induce haematologic and cytogenetic remission in patients with CML; but neuro- psychiatric complications of a -interferon (a-IFN) usage were not reported in Nigeria. Objective: To report a case of deliberate self-harm in University Lecturer as a side effect of a-IFN in the treatment of CML. Method: Clinical and laboratory follow up of a patient receiving a-IFN in the management of CML from the time of diagnosis of CML to the point of loss of contact. Result: Severe depression is a complication that may adversely influence the clinical outcome of a-IFN usage Conclusions/Recommendations: Although interferon related depression is uncommon; it is suggested that pre-therapy interferon assays and neuro-psychiatric assessment are carried out in prospective users of a-IFN